

Monday, March 31, 2008

COMPANY PRESS RELEASE

Transgenomic Opens Pharmacogenomics Laboratory in China
Provides New Opportunity to Serve Pharmaceutical
Partner Interest for Clinical Trials in China

OMAHA, Neb., March 31, 2008 – Transgenomic, Inc. ([OTC BB: TBIO.OB](#)), a global genetic analysis and services company, today announced that it has entered into a laboratory services agreement with the Guangzhou Family Planning Center in Guangzhou, China. Under this agreement, Transgenomic will partner with the Guangzhou Laboratory to provide pharmacogenomic analyses within the Guangzhou Laboratory for pharmaceutical companies who choose to pursue clinical trials in China. The company has already equipped the facility with the instrument system technology needed to provide these sophisticated pharmacogenomics services.

“Our partnership with the Guangzhou laboratory, coupled with our expanding expertise in conducting pharmacogenomics studies for pharmaceutical companies opens a new door of opportunity for our Pharmacogenomics business,” said Craig Tuttle, Transgenomic President and Chief Executive Officer. “Many of our Pharmaceutical partners are interested in pursuing clinical trials in China. Under Chinese law, samples collected in China must be tested in China. The Guangzhou laboratory provides the facility to enable us to offer our Pharmaceutical customers the testing capabilities they seek as they expand their clinical trial efforts to Asia, opening significant new clinical testing opportunities for us and strengthening our position as a leading supplier to our pharmaceutical partners in their worldwide efforts to bring new drugs to market.”

About Transgenomic:

Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Their offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine. Specific offerings include WAVE[®] DHPLC Systems, related consumables and assay kits, cytogenetics automated systems, Transgenomic Molecular Clinical Reference Laboratory and Pharmacogenomics Research Services. Transgenomic’s two laboratory services divisions utilize these technologies and expertise to provide a menu of mutation scanning tests for over 700 cancer-associated genes and more than 60 validated diagnostic tests to meet the needs of pharmaceutical and biotech companies, research and clinical laboratories, physicians and patients. For more information about the innovative systems, products and services offered by Transgenomic, please visit: www.transgenomic.com.

Transgenomic Cautionary Statements

Certain statements in this press release constitute “forward-looking statements” of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect

to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.